Workweek December 12, 2022
MARK CUBAN’S COST PLUS DRUGS’ NEXT TARGET: EMPLOYERS
On December 8, Mark Cuban Cost Plus Drugs (MCCPD) announced a partnership with EmsanaRx, a pharmacy benefit manager (PBM) created by the Purchaser Business Group on Health (PBGH) (seriously, what’s with the names guys – this isn’t a legal document). Together, MCCPD and EmsanaRx will launch an offering of MCCPD’s discounted cost-plus model targeting self-insured employers. As part of the deal, EmsanaRx, created back in October 2021 and also a public benefit corporation partnered with the Cleveland Clinic, will handle the tech and prescription fulfillment. It’ll collect a transparent 1.5% flat fee for each claim managed (AKA, passing on all rebates – upfront PBM pricing). The ultimate goal of the partnership aims...
Today's Sponsors
Today's Sponsor